Recently, at the 4th China Pharmaceutical Innovation and Investment Conference, Huang Guobin, head of China at JPMorgan Chase Global Investment Bank, pointed out that this year’s Hong Kong market has dropped by nearly half compared with last year, but the number of financing Increased, which means that the average level of single financing is much lower than last year, but the single financing of medical stocks has increased. The industry believes that there are still two hot spots in the current Hong Kong market in the medical and health industry. Opportunities and challenges coexist, hitting the two major hot spots in the medical and health industry hot one: the biotechnology sector
It is reported that from last year to the end of August this year, in the medical and health industry, the biotechnology sector has become a hot spot in the capital market. In 2018, the Hong Kong Stock Exchange allowed biotech companies that were not yet profitable to be listed.
Under this channel, many non-profitable biotech companies went public in Hong Kong, causing a boom in the biotech sector. Biopharmaceutical companies listed on the Hong Kong Stock Exchange, as well as existing innovative drug companies, such as Fuhong Henlius, which was listed on the Hong Kong stock market recently. Regarding why they chose to list on Hong Kong stocks, Dr. Liu Shigao, President and CEO of Fuhong Henlius, mentioned in an interview, ‘In 2018, the Hong Kong Stock Exchange issued regulations to allow biotech companies that have not yet made a profit to be listed, and we are ready to enter the Hong Kong stock market. It is natural to prepare for listing now.;
Of course, there are also biopharmaceutical companies with relatively comprehensive business. For example, Jiangsu Hausen, which went public in Assembly Machine Of Disposable Syringe this year, not only has an innovative drug industry, but also has pipelines covering generic drugs. In the past two years, the overall performance of pharmaceutical companies listed on the Hong Kong stock market has performed well. For example, as of August 28, 2019, WuXi Biologics has a market value of 99.1 billion Hong Kong dollars and a price-earnings ratio (PE) of 139; WuXi AppTec has a market value of 135 billion Hong Kong dollars and PE 59;
ainfusiondripe